On 26 july 2025, the first publicly available shipments of "slubber needle" deoxychoric acid injections, developed by the nanjing menowe pharmaceutical autonomously, were officially launched, and the first co-operative medical institutions will be inaugurated. As the first drug registration certificate and the first two-compliant resin injection product to adapt to injecting solubility, it fills a compliance gap in the area of injecting resin in the country's medical community。
It is known that the core ingredient of thioperidium is the same as that of kybella, listed in the united states, which directly destroys the fat cell membrane by targeting the fat cells in the injection area and reduces the number of fat cells; at the same time, it triggers a moderate inflammation response, activates the fibre cell, produces a natural tightening effect and achieves the dual effect of “fat reduction + tight skin”. In the international market, the united states of america acquired deoxychoric acid injections, the only product that received official european and united states approval for injections of resin, which were approved in the united states in 2015 and belkyraium in europe in 2016, for the purpose of “improving the medium-to-heavy contours of adult fat”. According to kybella's clinical data, the effect can last for at least four years (regarding the time of follow-up) and is comparable to the effect of the lipid operation. In the domestic market, menowe medicine, mei-002, was the first approved soluble needle in the country, while drug clinical services were initiated for the stellar species, tibetan shincon, cordi biology, beijing nobot and seok-woo pharmaceuticals, among which js-001 of the stellar species was in clinical phase iii; cu-20401 of the steroids was in clinical phase ii; and tibetan shincon, beijing nobot and saeyu pharmaceuticals were in clinical phase i。
00:37 hours
About the meenover medicine
Nanjing menowey medicines technology ltd., founded in february 2021 as a developer of new medicines in the spiritual and medical fields, dedicated to the development of innovative medicines in the spiritual, dermal and orthopaedic fields, has created a platform for the development and industrialization of small molecular innovations based on the new drug delivery system, providing appropriate drug delivery methods for those sources of innovation that cannot or do not work optimally。
The product pipeline of the menowe medicine focuses mainly on two areas, including mental and disfigured diseases. The main related hospital units are plastic surgery, dermatology, mainly those which impair the beauty of the human person or the body's health, including loss of hair, scabies, light damage, various colours, bruises, local adhesive accumulation, etc。
The menowey medicines have developed two product lines, “the beauty of the heart” and “the beauty of the image”, respectively, for mental and disfigured diseases. Of these, the country's first local solute deoxychoric acid injection, mei-005, was officially approved as the country's first local solute drug; the oral post-partum depression new pill, mi078 capsules, is in clinical stage ii; and the new antiquated aging-related adaptive drug, mi078 is currently in clinical development。
To date, the menowe medicine has been financed by the angel wheel, co-financed by nanjing norret and cube pharmaceuticals; by the tens of millions of pre-a rounds, led by yuanwon; by the multi-billion dollar a round, co-financed by huaijia capital, shangzawa capital and kimura health; and by the hundreds of millions of dollars pre-b round, co-financed by aquaquaqua and kyushu general, with a total financing of over $300 million and company valuation of $2 billion。
On 5 november 2024, the united states fda approved an application for a clinical study of a new mei-002 injection drug, which was developed autonomously by menover pharmaceuticals, and was used mainly to “reduce the accumulation of blubber”. It is known that this is a new injectable resin drug approved for clinical section 2 in menotwey and a new clinical drug approved for section 5。
On 10 june 2025, the national drug control agency (nds) officially approved the "oxygen cyric acid injection" developed in nanjing menowe under its own medical research, registration number h20254519, which is used mainly to improve the medium-to-heavy contours or over-exhausture caused by adult hypothermia, which is the first dose of soluble resin to be approved in the country。
